-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Past randomized controlled trials and meta-analysis have shown that concurrent chemotherapy or hyperfractionated radiotherapy for locally advanced head and neck cancer has a survival advantage.
The team of Dr.
A randomized controlled trial that evaluated chemotherapy and fractional radiotherapy for patients with non-metastatic head and neck squamous cell carcinoma conducted between January 1, 1980 and December 31, 2016 was included.
In total, 115 randomized controlled trials were included in this analysis, including 28,978 patients, 19,253 deaths, and 20579 progression events.
Diagram of the overall survival test network
Diagram of the overall survival test networkThe median follow-up time for these trials was 6.
The median follow-up time was 6.
Compared with CLRTP (P score 78%), the other three treatments have higher overall survival rate P score, but HR has not improved significantly
In summary, the results of this network meta-analysis show that the use of HFCRT or ICTaxPF-CLRT to further strengthen radiotherapy and chemotherapy is more effective than radiotherapy for locally advanced head and neck cancer .
Using HFCRT or ICaxPF-CLRT to further enhance the efficacy of radiotherapy and chemotherapy for locally advanced head and neck cancer.
Original source:
Claire Petit, et al.
org/10.
1016/S1470-2045(21)00076-0" target="_blank" rel="noopener">Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis in this message
